首页> 外文期刊>Infectious Diseases and Therapy >Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm
【24h】

Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm

机译:大剂量达托霉素对单独的万古霉素或与克拉霉素或利福平联用对金黄色葡萄球菌和表皮葡萄球菌的新型细菌生物膜体外PK / PD模型的评价

获取原文
           

摘要

Introduction Medical device infections are associated with significant morbidity and mortality. These difficult-to-treat infections often result in antibiotic failure and resistance. Combination therapy is often required, however, the most optimal combination is unknown. We evaluated the in vitro activity of daptomycin (DAP) or vancomycin (VAN) alone and in combination with rifampin (RIF) or clarithromycin (CLA) against strains of Staphylococcus aureus and S. epidermidis grown in biofilm on 3 prosthetic device materials.
机译:简介医疗器械感染与明显的发病率和死亡率有关。这些难以治疗的感染通常会导致抗生素失效和耐药。通常需要组合疗法,但是,最佳组合尚不清楚。我们评估了达托霉素(DAP)或万古霉素(VAN)单独使用以及与利福平(RIF)或克拉霉素(CLA)结合使用时对三种假体器械材料上生物膜中生长的金黄色葡萄球菌和表皮葡萄球菌菌株的体外活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号